Premium
Maternal Apolipoprotein B100 Serum Levels are Diminished in Pregnancies with Intrauterine Growth Restriction and Differentiate from Controls
Author(s) -
Wölter Manja,
Okai Charles A.,
Smith Derek S.,
Ruß Manuela,
Rath Werner,
Pecks Ulrich,
Borchers Christoph H.,
Glocker Michael O.
Publication year - 2018
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201800017
Subject(s) - intrauterine growth restriction , apolipoprotein b , multiplex , fetus , pregnancy , medicine , fetal growth , physiology , andrology , obstetrics , endocrinology , biology , cholesterol , bioinformatics , genetics
Purpose Intrauterine growth restriction, a major cause of fetal morbidity and mortality, is defined as a condition in which the fetus does not reach its genetically given growth potential. Screening for intrauterine growth restriction biomarkers in the mother's blood would be of great help for optimal pregnancy management and timing of delivery as well as for identifying fetuses requiring further surveillance during their infancies. Experimental Design A multiplexing serological assay based on liquid chromatography–multiple‐reaction‐monitoring mass spectrometry is applied for distinguishing serum samples of pregnant women. Results Assessment of concentrations of apolipoproteins and of proteins that belong to the lipid transport system is performed with maternal serum samples, consuming only 10 μL of serum per multiplex assay from each patient. Of all investigated proteins the serum concentrations of apolipoprotein B100 shows the greatest power for discriminating intrauterine growth restriction from control samples, reaching areas under curves above 0.85 in receiver‐operator‐characteristics analyses. Conclusions These results indicate the potential of liquid chromatography‐multiple‐reaction‐monitoring mass spectrometry to become of clinical importance in the future for intrauterine growth restriction risk assessment based on maternal apolipoprotein B100 serum levels.